Igene Biotechnology, Inc.
IGNE · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -48.2% | 234.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 25.7% | 16.3% | 26.5% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -27% | -28.6% | 10.4% | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.6% | -52.2% | -83% | – |
| EPS | -0 | -0.021 | -0.017 | -0.011 |
| % Growth | 99.5% | -23.1% | -61.7% | – |
| EPS Diluted | -0 | -0.021 | -0.017 | -0.011 |
| Weighted Avg Shares Out | 2 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -21.5% | -27.2% | 14.2% | – |